Literature DB >> 29902598

Deregulation of the Hippo Pathway Promotes Tumor Cell Proliferation Through YAP Activity in Human Sporadic Vestibular Schwannoma.

Fu Zhao1, Zhijun Yang2, Yang Chen3, Qiangyi Zhou4, Jing Zhang4, Jiang Liu5, Bo Wang6, Qiyang He3, Li Zhang5, Yanbing Yu7, Pinan Liu2.   

Abstract

OBJECTIVE: Vestibular schwannomas (VSs) can cause serious neurological defects including hearing loss and facial paralysis. The aim of this study is to identify whether Hippo signaling could be a potential targetable pathway for clinical treatment in VSs.
METHODS: Gene expression profiling was performed in 10 sporadic VSs and 4 normal nerves to identify aberrant genes expression of the Hippo pathway. Western blotting and immunohistochemical staining were used to examine the expression of Hippo core components in 20 VS samples. Neurofibromatosis type 2 (NF2) gene sequencing was also performed in all tumors using sanger sequencing. Verteporfin, inhibitor of yes-associated protein (YAP)-TEA domain family member, was used to assess the effect of proliferation inhibition in human primary VS cells and RT4-D6P2T cell line.
RESULTS: We found 51 differentially expressed genes of the Hippo pathway between VSs and healthy controls. Unsupervised analysis identified the 2 molecular variants that significantly related with distinct NF2 mutation status. The phosphorylation levels of large tumor suppressor 1 and YAP were significantly decreased in NF2-mutated VSs compared with wild-type VSs and normal nerves. Immunohistochemical staining showed that increased nuclear YAP expression in VSs was positively correlated with high Ki-67 index and low Merlin expression. Verteporfin reduced viability of primary VS cells and RT4-D6P2T cells.
CONCLUSIONS: Our findings implicate that deregulation of the Hippo pathway as a molecular mechanism of pathogenesis in human VSs, and suggest inhibition of this pathway as a potential treatment strategy.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell proliferation; Hippo pathway; NF2; Vestibular schwannoma; YAP

Mesh:

Substances:

Year:  2018        PMID: 29902598     DOI: 10.1016/j.wneu.2018.06.010

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

Review 1.  Understanding the Molecular Mechanism of Vestibular Schwannoma for Hearing Preservation Surgery: Otologists' Perspective from Bedside to Bench.

Authors:  Makoto Hosoya; Takeshi Wakabayashi; Koichiro Wasano; Takanori Nishiyama; Nobuyoshi Tsuzuki; Naoki Oishi
Journal:  Diagnostics (Basel)       Date:  2022-04-21

2.  Somatic Mutations of lats2 Cause Peripheral Nerve Sheath Tumors in Zebrafish.

Authors:  Zachary J Brandt; Paula N North; Brian A Link
Journal:  Cells       Date:  2019-08-25       Impact factor: 6.600

3.  Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma.

Authors:  Jessica E Sagers; Roberta L Beauchamp; Yanling Zhang; Sasa Vasilijic; Limeng Wu; Patrick DeSouza; Richard Seist; Wenjianlong Zhou; Lei Xu; Vijaya Ramesh; Konstantina M Stankovic
Journal:  Sci Rep       Date:  2020-03-06       Impact factor: 4.379

4.  Whole Genome Sequencing Identifies Key Genes in Spinal Schwannoma.

Authors:  Xin Gao; Li Zhang; Qi Jia; Liang Tang; Wen Guo; Tao Wang; Zheyu Wu; Wang Zhou; Zhenxi Li; Jianru Xiao
Journal:  Front Genet       Date:  2020-10-30       Impact factor: 4.599

5.  The Role of Magnetic Resonance Imaging (MRI) in Diagnostics of Acoustic Schwannoma.

Authors:  Serbeze Kabashi; Mehmet Sahin Ugurel; Kreshnike Dedushi; Sefedin Mucaj
Journal:  Acta Inform Med       Date:  2020-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.